Literature DB >> 19887421

Innovation in Namibia: preserving private health insurance and HIV/AIDS treatment.

Onno P Schellekens1, Ingrid de Beer, Marianne E Lindner, Michele van Vugt, Peter Schellekens, Tobias F Rinke de Wit, Tobias F Rinke de Wit.   

Abstract

Namibia, a lower-middle-income country in sub-Saharan Africa, suffers from a huge HIV/AIDS burden. An influx of donor funding in 2004-2007 increased support for publicly provided HIV care and treatment. This raised concern that private funding would be "crowded out," thereby leading to a reduction in the overall resources used to treat patients. In 2006 the Namibian medical aid industry, with donor support, created a special fund to subsidize private health insurance, including HIV/AIDS services. The program allowed both low- and higher-income people to be covered. Crowding out valuable private resources was avoided and the quality of HIV/AIDS services improved.

Entities:  

Mesh:

Year:  2009        PMID: 19887421     DOI: 10.1377/hlthaff.28.6.1799

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  3 in total

1.  Incidence of HIV in Windhoek, Namibia: demographic and socio-economic associations.

Authors:  Marielle Aulagnier; Wendy Janssens; Ingrid De Beer; Gert van Rooy; Esegiel Gaeb; Cees Hesp; Jacques van der Gaag; Tobias F Rinke de Wit
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

2.  A digital mobile health platform increasing efficiency and transparency towards universal health coverage in low- and middle-income countries.

Authors:  Liesbeth Huisman; Shannen Mc van Duijn; Nuno Silva; Rianne van Doeveren; Jacinta Michuki; Moses Kuria; David Otieno Okeyo; Isaiah Okoth; Nathalie Houben; Tobias F Rinke de Wit; Khama Rogo
Journal:  Digit Health       Date:  2022-04-11

3.  Where will the money come from? Alternative mechanisms to HIV donor funding.

Authors:  Itamar Katz; Subrata Routh; Ricardo Bitran; Alexandra Hulme; Carlos Avila
Journal:  BMC Public Health       Date:  2014-09-16       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.